Literature DB >> 2566929

Neuronally released (-)-noradrenaline relaxes smooth muscle of calf trachea mainly through beta 1-adrenoceptors: comparison with (-)-adrenaline and relation to adenylate cyclase stimulation.

H Lemonine1, G E Novotny, A J Kaumann.   

Abstract

The nature of the receptors that mediate the relaxation of smooth muscle by field stimulation, (-)-noradrenaline and (-)-adrenaline was investigated in calf tracheal smooth muscle. The relation between relaxation, stimulation of the adenylate cyclase and density of beta-adrenoceptor subtypes was studied with the help of antagonists of beta 1- and beta 2-adrenoceptors. The question of the existence of catecholamine-containing nerves was also investigated. (1) Nerves with varicosities exhibiting catecholaminergic fluorescence were observed between bundles of smooth muscle cells. (2) Consistent with the existence of adrenergic nerves (-)-noradrenaline was also found. The content of (-)-noradrenaline (1 microgram.g-1 w.w.) was the same in smooth muscle strips from the sublaryngeal region and from the region close to the bifurcation of the calf trachea. (-)-Adrenaline was not detected. (3) Smooth muscle relaxation by low (-)-noradrenaline concentration (0.6-2 nmol/l) was mediated through beta 1-adrenoceptors. Low concentrations of (-)-adrenaline (0.06-1 nmol/l) relaxed through beta 2-adrenoceptors. High concentrations of (-)-noradrenaline and (-)-adrenaline also caused relaxation through beta 2- and beta 1-adrenoceptors respectively. (4) Field stimulation caused relaxation which was half maximal at 0.2-0.8 Hz. Blockade of beta 1-adrenoceptors strongly attenuated the relaxant response to field stimulation and shifted the frequency-relaxation curves to 4 times higher frequencies. These results are consistent with a beta 1-adrenoceptor-mediated relaxation caused by (-)-noradrenaline released from sympathetic nerve endings at low stimulation frequencies. (5) Blockade of beta 2-adrenoceptors failed to reduce smooth muscle relaxation caused by field stimulation at low stimulation frequencies (0.1-1 Hz). However, after beta 1-adrenoceptor blockade, additional blockade of beta 2-adrenoceptors reduced the relaxant effects observed at high frequencies (2-400 Hz). The results suggest that high concentrations of endogenous (-)-noradrenaline cause relaxation through beta 2-adrenoceptors. (6) Binding experiments with 3H-(-)-bupranolol and 3H-ICI 118,551 revealed between 10,000 and 20,000 beta-adrenoceptors per smooth muscle cell of which 3/4 were beta 2 and 1/4 beta 1. The equilibrium dissociation constant of (-)-adrenaline for both beta 1- and beta 2-adrenoceptors and of (-)-noradrenaline for beta 1-adrenoceptors was 1 mumol/l. The affinity of (-)-noradrenaline for beta 2-adrenoceptors was 10 to 20 times lower than for beta 1-adrenoceptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566929     DOI: 10.1007/BF00165131

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  55 in total

1.  Sympathetic versus parasympathetic nervous regulation of airways in dogs.

Authors:  G A Cabezas; P D Graf; J A Nadel
Journal:  J Appl Physiol       Date:  1971-11       Impact factor: 3.531

Review 2.  Innervation of airway smooth muscle: fine structure.

Authors:  G Gabella
Journal:  Annu Rev Physiol       Date:  1987       Impact factor: 19.318

3.  A model for the interaction of competitive antagonists with two receptor-subtypes characterized by a Schild-plot with apparent slope unity. Agonist-dependent enantiomeric affinity ratios for bupranolol in tracheae but not in right atria of guinea pigs.

Authors:  H Lemoine; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

4.  On equilibrium dissociation constants for complexes of drug-receptor subtypes. Selective and non-selective interactions of partial agonists with two plausible beta-adrenoceptor subtypes mediating positive chronotropic effects of (-)-isoprenaline in kitten atria.

Authors:  A J Kaumann; M Marano
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-02       Impact factor: 3.000

5.  Improved evaluation of binding of ligands to membranes containing several receptor-subtypes.

Authors:  B Ehle; H Lemoine; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

Review 6.  Alpha-adrenoceptor subclassification.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1981       Impact factor: 5.545

7.  Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(-)-bisoprolol with its blocking potency.

Authors:  A J Kaumann; H Lemoine
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

8.  Effect of calmodulin, Ca2+, and cAMP protein kinase on skinned tracheal smooth muscle.

Authors:  M P Sparrow; G Pfitzer; M Gagelmann; J C Rüegg
Journal:  Am J Physiol       Date:  1984-03

9.  The affinity of (-)-propranolol for beta 1- and beta 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline.

Authors:  E Gille; H Lemoine; B Ehle; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

10.  Comparison of functional beta-adrenoceptor heterogeneity in central and peripheral airway smooth muscle of guinea pig and man.

Authors:  J Zaagsma; P J van der Heijden; M W van der Schaar; C M Bank
Journal:  J Recept Res       Date:  1983
View more
  8 in total

1.  Pharmacological characterization of the beta-adrenoceptor that mediates the relaxant response to noradrenaline in guinea-pig tracheal smooth muscle.

Authors:  Yoshio Tanaka; Yoko Yamashita; Hiromi Michikawa; Takahiro Horinouchi; Katsuo Koike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-20       Impact factor: 3.000

2.  Characterization of endogenous noradrenaline release from intact and epithelium-denuded rat isolated trachea.

Authors:  K Racké; A Bähring; G Brunn; M Elsner; I Wessler
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

3.  Regional differences of beta 1- and beta 2-adrenoceptor-mediated functions in feline heart. A beta 2-adrenoceptor-mediated positive inotropic effect possibly unrelated to cyclic AMP.

Authors:  H Lemoine; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

4.  On minimum cyclic AMP formation rates associated with positive inotropic effects mediated through beta 1-adrenoceptors in kitten myocardium. Beta 1-specific and non-adrenergic stimulant effects of denopamine.

Authors:  H Lemoine; K J Teng; S J Slee; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

5.  Formoterol, fenoterol, and salbutamol as partial agonists for relaxation of maximally contracted guinea pig tracheae: comparison of relaxation with receptor binding.

Authors:  H Lemoine; C Overlack; A Köhl; H Worth; D Reinhardt
Journal:  Lung       Date:  1992       Impact factor: 2.584

6.  Selective and full beta 1-adrenoceptor agonist action of a catechol derivative of denopamine (T-0509) in the guinea-pig cardiac muscle and trachea: comparison with denopamine, xamoterol and isoprenaline.

Authors:  H Yabana; H Watanabe; H Narita; T Nagao
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

7.  Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle.

Authors:  K E Ellis; R Mistry; J P Boyle; R A Challiss
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

8.  Comparison of the effects of selective inhibitors of phosphodiesterase types III and IV in airway smooth muscle with differing beta-adrenoceptor subtypes.

Authors:  A Tomkinson; J A Karlsson; D Raeburn
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.